Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension

References

• Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA290(2), 199–206 (2003).
   Google Scholar
• Thaker D, Frech F, Suh D et al. Prevalence of hypertension and ethnic differences in sociodemographic and cardiovascular health characteristics of US hypertensives. Am. J. Hypertens.18(5), A117 (2005).
   Web of Science ®Google Scholar
• Hypertension in America: a national reading. Am. J. Manag. Care11(Suppl. 13), S383–S385 (2005).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension42(6), 1206–1252 (2003).
   PubMed Web of Science ®Google Scholar
• The ALLHAT Officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering treatment to Prevent Heart Attack Trial (ALLHAT). JAMA288(23), 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• Black HR, Eliott WJ, Grandits G et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End points (CONVINCE) trial. JAMA289(16), 2073–2082 (2003).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet359(9311), 995–1003 (2002).
   PubMed Web of Science ®Google Scholar
• Logan AG, Perlikowski SM, Mente A et al. High prevalence of unrecognized sleep apnea in drug-resistant hypertension. J. Hypertens.19(12), 2271–2277 (2001).
   PubMed Web of Science ®Google Scholar
• Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin. Exp. Pharmacol. Physiol.21(4), 315–318 (1994).
   PubMed Web of Science ®Google Scholar
• Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin. Exp. Pharmacol. Physiol.20, 296–298 (1993).
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension40(6), 892–896 (2002).
   PubMed Web of Science ®Google Scholar
• Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone–renin ratio. Am. J. Kidney Dis.37(4), 699–705 (2001).
   PubMed Web of Science ®Google Scholar
• Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J. Hypertens.22(11), 2217–2226(2004).
   PubMed Web of Science ®Google Scholar
• Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J. Hum. Hypertens.17(5), 349–352 (2003).
   PubMed Web of Science ®Google Scholar
• Conn JW. The evolution of primary aldosteronism. Harvey Lect.62, 257–291 (1968).
   Google Scholar
• Bravo El, Tarazi RC, Dustan HP et al. The changing clinical spectrum of primary aldosteronism. Am. J. Med.74(4), 641–651 (1983).
   PubMed Web of Science ®Google Scholar
• Benchetrit S, Bernheim J, Podjarny E. Normokalemic hyperaldosteronism in patients with resistant hypertension. Isr. Med. Assoc. J.4(1), 17–20 (2002).
   Google Scholar
• Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am. J. Hypertens.16(11 Pt 1), 925–930 (2003).
   PubMed Web of Science ®Google Scholar
• Becker HF, Jerrentrup A, Ploch T et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation107(1), 68–73 (2003).
   PubMed Web of Science ®Google Scholar
• Logan AG, Tkacova R, Perlikowski SM et al. Refractory hypertension and sleep apnea: effect of CPAP on blood pressure and baroreflex. Eur. Respir. J.21(2), 241–247 (2003).
   PubMed Web of Science ®Google Scholar
• Vollmer WM, Sacks FM, Ard J et al. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann. Intern. Med.135(12), 1019–1028 (2001).
   PubMed Web of Science ®Google Scholar
• Garg JP. Elliott WJ, Folker A et al. Resistant hypertension revisited: a comparision of two university based cohorts. Am. J. Hypertens.18(5 Pt 1), 619–26 (2005).
   PubMed Web of Science ®Google Scholar
• Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J. Hypertens.15(4 Pt 1), 333–339 (2002).
   Google Scholar
• Saha C, Eckert GJ, Ambrosius WT et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension46(3), 481–487 (2005).
   PubMed Web of Science ®Google Scholar
• Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J. Hypertens.15(8), 709–716 (2002).
   Google Scholar
• White WB, Duprez D, Hillaire RS et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension41(5), 1021–1026 (2003).
   PubMed Web of Science ®Google Scholar
• Williams GH, Burgess E, Kolloch RE et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am. J. Cardiol.93(8), 990–6 (2004).
   PubMed Web of Science ®Google Scholar
• Flack JM, Oparil S, Pratt H et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J. Am. J. Cardiol.41(7), 1148–1155 (2003).
   PubMed Web of Science ®Google Scholar
• Krum H, Nolly H, Workman D et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension40(2), 117–23 (2002).
   PubMed Web of Science ®Google Scholar
• Goodfriend TL, Ball DL, Gardner HW. An oxidized derivative of linoleic acid affects aldosterone secretion by adrenal cells in vitro. Prostaglandins Leukot Essent Fatty Acids67(2–3), 163–167 (2002).
   Google Scholar
• Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest125(1), 112–117 (2004).
   PubMed Web of Science ®Google Scholar
• Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. J. Hypertension.22, 863–869 (2004)
   PubMed Web of Science ®Google Scholar